WO2000020591A3 - Tgf-beta superfamily mutant members, including morphogenic proteins - Google Patents

Tgf-beta superfamily mutant members, including morphogenic proteins Download PDF

Info

Publication number
WO2000020591A3
WO2000020591A3 PCT/US1999/023370 US9923370W WO0020591A3 WO 2000020591 A3 WO2000020591 A3 WO 2000020591A3 US 9923370 W US9923370 W US 9923370W WO 0020591 A3 WO0020591 A3 WO 0020591A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
proteins
morphogenic proteins
beta superfamily
members
Prior art date
Application number
PCT/US1999/023370
Other languages
French (fr)
Other versions
WO2000020591A2 (en
WO2000020591A9 (en
Inventor
Hermann Oppermann
Mei-Sheng Tai
John Mccartney
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Priority to AU11037/00A priority Critical patent/AU772934B2/en
Priority to EP99954770A priority patent/EP1117795B1/en
Priority to CA2345287A priority patent/CA2345287C/en
Priority to JP2000574686A priority patent/JP3982995B2/en
Priority to DE69934418T priority patent/DE69934418T2/en
Publication of WO2000020591A2 publication Critical patent/WO2000020591A2/en
Publication of WO2000020591A3 publication Critical patent/WO2000020591A3/en
Publication of WO2000020591A9 publication Critical patent/WO2000020591A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

The invention provides modified proteins and DNAs of the TGF-β superfamily including modified morphogenic proteins. The proteins of the present invention display altered biological or biochemical attributes. Specifically, the modified proteins are designed through manipulation of exchange of subdomains among two or more members of the superfamily such that certain desired attributes are mixed-and-matched and then exploited therapeutically.
PCT/US1999/023370 1998-10-07 1999-10-07 Tgf-beta superfamily mutant members, including morphogenic proteins WO2000020591A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU11037/00A AU772934B2 (en) 1998-10-07 1999-10-07 TGF-beta superfamily mutant members, including morphogenic proteins
EP99954770A EP1117795B1 (en) 1998-10-07 1999-10-07 Tgf-beta superfamily mutant members, including morphogenic proteins
CA2345287A CA2345287C (en) 1998-10-07 1999-10-07 Tgf-beta superfamily mutant members, including morphogenic proteins
JP2000574686A JP3982995B2 (en) 1998-10-07 1999-10-07 TGF-β superfamily mutant members containing morphogenic proteins
DE69934418T DE69934418T2 (en) 1998-10-07 1999-10-07 MUTED MEMBERS OF THE TGF BETA SUPERFAMILY, INCLUDING MORPHOGENETIC PROTEINS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10341898P 1998-10-07 1998-10-07
US09/374,936 1999-08-16
US09/374,936 US6846906B1 (en) 1998-10-07 1999-08-16 Modified proteins of the TGF-β superfamily, including morphogenic proteins
US60/103,418 1999-08-16

Publications (3)

Publication Number Publication Date
WO2000020591A2 WO2000020591A2 (en) 2000-04-13
WO2000020591A3 true WO2000020591A3 (en) 2000-07-06
WO2000020591A9 WO2000020591A9 (en) 2001-03-22

Family

ID=26800440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023370 WO2000020591A2 (en) 1998-10-07 1999-10-07 Tgf-beta superfamily mutant members, including morphogenic proteins

Country Status (8)

Country Link
US (1) US6846906B1 (en)
EP (1) EP1117795B1 (en)
JP (2) JP3982995B2 (en)
AT (1) ATE348159T1 (en)
AU (1) AU772934B2 (en)
CA (1) CA2345287C (en)
DE (1) DE69934418T2 (en)
WO (1) WO2000020591A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919308B2 (en) * 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US7524625B2 (en) 2000-10-30 2009-04-28 Sru Biosystems, Inc. Real time binding analysis of antigens on a biosensor surface
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
JP5100662B2 (en) * 2005-12-22 2012-12-19 セントカー・インコーポレーテツド BMP-7 variant compositions, methods and uses
US7659250B2 (en) 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
WO2008082563A2 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
EP2019117A1 (en) * 2007-07-27 2009-01-28 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Optimized purification process of recombinant growth factor protein
AU2010213575B2 (en) 2009-02-12 2013-11-14 Stryker Corporation Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
US20100204124A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
CA2752647A1 (en) * 2009-02-24 2010-09-02 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
CA2774024A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
AU2010341565A1 (en) 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity
CN103079585B (en) 2010-08-20 2015-09-30 惠氏有限责任公司 Through the BMP of design
CA2977625A1 (en) 2014-12-29 2016-07-07 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008480A1 (en) * 1990-11-16 1992-05-29 Celtrix Pharmaceuticals, Inc. A β-TYPE TRANSFORMING GROWTH FACTOR
WO1992016228A1 (en) * 1991-03-14 1992-10-01 Bristol-Myers Squibb Company TGF-β1/β2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA
EP0626451A2 (en) * 1993-05-27 1994-11-30 Takeda Chemical Industries, Ltd. Heterodimers of a TGF-beta superfamily
EP0723013A2 (en) * 1988-04-08 1996-07-24 Stryker Corporation Biosynthetic osteogenic proteins and osteogenic devices containing them

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250302A (en) 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
DK0448704T3 (en) 1989-10-17 1999-04-06 Stryker Corp Osteogenic devices
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
ATE203166T1 (en) 1991-03-11 2001-08-15 Curis Inc PROTEIN-INDUCING MORPHOGENESIS
JP3645258B2 (en) 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Growth and differentiation factor-5
CA2165776A1 (en) 1993-07-09 1995-01-19 Se-Jin Lee Growth differentiation factor-6
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
JP3717930B2 (en) 1993-12-07 2005-11-16 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー BMP-12, BMP-13 and their tendon-derived compositions
WO1996014335A1 (en) * 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5674292A (en) 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723013A2 (en) * 1988-04-08 1996-07-24 Stryker Corporation Biosynthetic osteogenic proteins and osteogenic devices containing them
WO1992008480A1 (en) * 1990-11-16 1992-05-29 Celtrix Pharmaceuticals, Inc. A β-TYPE TRANSFORMING GROWTH FACTOR
WO1992016228A1 (en) * 1991-03-14 1992-10-01 Bristol-Myers Squibb Company TGF-β1/β2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA
EP0626451A2 (en) * 1993-05-27 1994-11-30 Takeda Chemical Industries, Ltd. Heterodimers of a TGF-beta superfamily

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENO CHIKARA ET AL.: "Two closely-related left-right asymmetrically expressed gens, lefty-1 and lefty-2 : their distinct expression domains, chromosomal linkage and direct neuralizing activity in Xenopus embryos", GENES TO CELLS, vol. 2, no. 8, 1997, pages 513 - 524, XP000892853 *
SU WEN QIAN ET AL: "BINDING AFFINITY OF TRANSFORMING GROWTH FACTOR-BETA FOR ITS TYPE IIRECEPTOR IS DETERMINED BY THE C-TERMINAL REGION OF THE MOCELCULE", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 48, 29 November 1996 (1996-11-29), pages 30656 - 30662, XP000197669, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP1117795B1 (en) 2006-12-13
JP2002526111A (en) 2002-08-20
CA2345287A1 (en) 2000-04-13
WO2000020591A2 (en) 2000-04-13
AU772934B2 (en) 2004-05-13
EP1117795A2 (en) 2001-07-25
AU1103700A (en) 2000-04-26
DE69934418D1 (en) 2007-01-25
ATE348159T1 (en) 2007-01-15
US6846906B1 (en) 2005-01-25
WO2000020591A9 (en) 2001-03-22
JP3982995B2 (en) 2007-09-26
CA2345287C (en) 2011-12-06
DE69934418T2 (en) 2007-10-25
JP2005287515A (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2000020607A3 (en) Chimaeric proteins between members of tgf-beta superfamily
WO2000020591A3 (en) Tgf-beta superfamily mutant members, including morphogenic proteins
AU2802197A (en) Biologically active fragment of (bacillus stearothermophilus) dna polymerase
EP2128260A3 (en) Modified TGF-beta superfamily proteins
AU8767198A (en) (thermococcus barosii) dna polymerase mutants
CA2232242A1 (en) Long wavelength engineered fluorescent proteins
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
ZA986475B (en) Thermodynamically stable modification of 1-(4-carbazoly loxy)3-[2-)2-methoxyphenoxy)ethylamino]-2-propanole, and pharmaceutical compositions containing it.
EP1312684A3 (en) Quantitative multiplex PCR with high dynamic range
AU4963797A (en) Rapid microbiological assay
AU2002314181A1 (en) Novel endothelially expressed dnas and proteins, and their use
AU5906699A (en) (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
WO2001064837A3 (en) β NETRIN AND USES THEREOF
CA2330025A1 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
WO1999039009A8 (en) Processes for isolating, amplifying and characterizing dna
AU3288497A (en) Mammalian tolloid-like gene and protein
AU4942597A (en) Thermostable dna polymerase from (anaerocellum thermophilum)
AU5971598A (en) Novel antibody, renin-active substance containing the same and prorenin assay reagent using the same
AU8987998A (en) Oligonucleotide specific of the (escherichia coli) species and method for detecting and displaying bacteria of this species
AU2002226074A1 (en) E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof
AU2224197A (en) Drug trial assay system
AU5186396A (en) Hematophagous insect calreticulin nucleic acid molecules, proteins and uses thereof
AU1690200A (en) Novel protein and dna thereof
AU4245096A (en) Biologically active fragments of thermus flavus dna polymerase

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11037

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1999954770

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11037/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2345287

Country of ref document: CA

Ref country code: CA

Ref document number: 2345287

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574686

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999954770

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 11037/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999954770

Country of ref document: EP